Overview
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing highly selective small-molecule therapeutics that modulate the mTORC1 pathway to restore cellular metabolic quality control. The company targets dysregulated growth and hyperactive signaling in rare genetic and age-related diseases, with its lead candidate AV078 currently in Phase 1 trials for tuberous sclerosis complex refractory epilepsy. Aeovian's proprietary platform encompasses both mTORC1 and CD38 inhibitors designed to address underlying disease mechanisms while minimizing off-target effects. The company's mission centers on translating fundamental aging biology into therapeutic interventions that improve healthspan and address unmet medical needs in rare and age-related conditions.